Julien Edeline - Concepedia

Author

Julien Edeline

Also Known As

Didier Samuel, Edeline, J, Edeline, J., Edeline, Julien, J Edeline, J. Edeline, J., Edeline, Julien EDELINE, Julien Edeline, S Walker

374

Publications

18.1K

Citations

H-Index

Concepts

All Affiliations

Centre Eugène Marquis Inserm Université de Rennes Centre Hospitalier Universitaire de Rennes Assistance Publique – Hôpitaux de Paris

About

Julien Edeline is an author at Centre Eugène Marquis specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	62	9.7K
2	Health Sciences	21	34	6.6K
3	Cell Biology	1	1	56
4	Diagnostic Sciences	1	1	210
5	Emergency Medicine	1	1	32

Julien Edeline

103

Publications

13K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Andrew X. Zhu, Richard S. Finn, Julien Edeline, The Lancet Oncology Open-label Phase 2HepatologyMedicineClinical TrialsPathology	2018	2.5K
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Journal of Clinical Oncology	2019	1.8K
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, The Lancet UrologySurgical OncologyGastrointestinal OncologyMedicineBiliary Cancer	2023	891
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Thomas Yau, J.W. Park, Richard S. Finn, Annals of Oncology HepatologyMedicineCheckmate 459Liver CancerAdvanced Hepatocellular Carcinoma	2019	639
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial Étienne Garin, Lambros Tselikas, Boris Guiu, The Lancet. Gastroenterology & hepatology Open-label Phase 2Radiation TherapyMedicineRadiation DoseDosimetry	2020	568
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Arndt Vogel, John Bridgewater, Julien Edeline, Annals of Oncology Surgical OncologyGastrointestinal OncologyMedicineCancer ManagementBiliary Cancer	2022	552
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study Julien Edeline, M. Benabdelghani, Aurélie Bertaut, Journal of Clinical Oncology	2019	504
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Josep M. Llovet, Masatoshi Kudo, Philippe Merle, The Lancet Oncology OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib	2023	364
Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma Julien Edeline, Yann Touchefeu, Boris Guiu, JAMA Oncology	2019	277
Dosimetry Based on <sup>99m</sup>Tc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with <sup>90</sup>Y-Loaded Glass Microspheres: Preliminary Results Étienne Garin, Laurence Lenoir, Yan Rolland, Journal of Nuclear Medicine	2012	273

Page 1